| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash | 7,729 | 4,766 | ||
| Restricted cash | 75 | 75 | ||
| Tax credit receivable | 513 | 1,642 | ||
| Prepaid expenses and other current assets | 465 | 282 | ||
| Total current assets | 8,782 | 6,765 | ||
| Total property and equipment | 2,094 | - | ||
| Less accumulated depreciation and amortization | 1,988 | - | ||
| Property and equipment, net | 106 | 107 | ||
| Deposits | 90 | 88 | ||
| Operating lease right-of-use assets, net (including 115 and 152 respectively, to related party) | 1,468 | 1,545 | ||
| Total assets | 10,446 | 8,505 | ||
| Accounts payable and accrued expenses | 1,194 | 1,514 | ||
| Current maturities of operating lease liabilities (including 54 and 49 respectively, to related party) | 326 | 317 | ||
| Total current liabilities | 1,520 | 1,831 | ||
| Operating lease liabilities (including 63 and 104 respectively, to related party) | 1,257 | 1,341 | ||
| Total long-term liabilities | - | 1,341 | ||
| Total liabilities | 2,777 | 3,172 | ||
| Common stock, 0.001 par value 100,000 shares authorized as of september 30, 2025 and december 31, 2024 13,041 and 10,174 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 13 | 10 | ||
| Additional paid-in capital | 347,479 | 343,097 | ||
| Accumulated deficit | -339,823 | -337,774 | ||
| Total stockholders equity | 7,669 | 5,333 | ||
| Total liabilities and stockholders equity | 10,446 | 8,505 | ||
Cocrystal Pharma, Inc. (COCP)
Cocrystal Pharma, Inc. (COCP)